Asia Pacific biodefense market will grow by 7.8% annually over 2020-2030 with a total addressable market cap of $15.8 billion in the fast-growing region despite the COVID-19 impact.
Highlighted with 32 tables and 40 figures, this 108-page report “Asia Pacific Biodefense Market 2020-2030 by Product (Vaccines, Detection Devices, Antibiotics, Masks), Sales Channel, Application (Military, Civilian), and Country: Trend Forecast and Growth Opportunity” is based on a comprehensive research of the entire Asia Pacific biodefense market and all its sub-segments through extensively detailed classifications.
Profound analysis and assessment are generated from premium primary and secondary information sources with inputs derived from industry professionals across the value chain. The report is based on studies on 2015-2019 and provides forecast from 2020 till 2030 with 2019 as the base year. (Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.)
In-depth qualitative analyses include identification and investigation of the following aspects:
• Market Structure
• Growth Drivers
• Restraints and Challenges
• Emerging Product Trends & Market Opportunities
• Porter’s Fiver Forces
The trend and outlook of Asia Pacific market is forecast in optimistic, balanced, and conservative view by taking into account of COVID-19. The balanced (most likely) projection is used to quantify Asia Pacific biodefense market in every aspect of the classification from perspectives of Product, Sales Channel, Application, and Country.
Based on Product, the Asia Pacific market is segmented into the following sub-markets with annual revenue for 2019-2030 included in each section.
Vaccines
• Anthrax
• Smallpox
• Botulism
• Nuclear/Radiation
• E-Bola
• Zika
• Other Vaccines
Biothreat Detection Devices
• Detectors/Triggering Devices
• Assays and Reagents
• Samplers
• Identifiers
Antibiotics
Masks
Other Products
Based on Sales Channel, the Asia Pacific market is segmented into the following sub-markets with annual revenue for 2019-2030 included in each section.
• Online Sales
• Offline Sales
Based on Application, the Asia Pacific market is segmented into the following sub-markets with annual revenue for 2019-2030 included in each section.
• Military
• Civilian
Geographically, the following national/local markets are fully investigated:
• Japan
• China
• South Korea
• Australia
• India
• Rest of APAC (further segmented into Malaysia, Singapore, Indonesia, Thailand, New Zealand, Vietnam, and Sri Lanka)
For each aforementioned country, detailed analysis and data for annual revenue are available for 2019-2030. The breakdown of key national markets by Product, Sales Channel, and Application over the forecast years is also included.
The report also covers current competitive scenario and the predicted trend; and profiles key vendors including market leaders and important emerging players.
Specifically, potential risks associated with investing in Asia Pacific biodefense market are assayed quantitatively and qualitatively through GMD’s Risk Assessment System. According to the risk analysis and evaluation, Critical Success Factors (CSFs) are generated as a guidance to help investors & stockholders identify emerging opportunities, manage and minimize the risks, develop appropriate business models, and make wise strategies and decisions.
Key Players (this may not be a complete list and extra companies can be added upon request):
Achaogen, Inc.
Alexeter Technologies LLC
Alnylam Pharmaceuticals, Inc.
Altimmune, Inc.
Bavarian Nordic AS
BioFactura, Inc.
Cleveland Biolabs, Inc.
Dynavax Technologies Inc
Dynport Vaccine Company LLC (DVC)
Elusys Therapeutics, Inc.
Emergent BioSolutions Inc
General Dynamics Corp.
GlaxoSmithKline Plc
Ichor Medical Systems
Mediimmune (AstraZeneca)
Nanotherapeutics, Inc.
Ology Bioscience
PathSensors Inc
Pluristem Therapeutics
Sanofi Pasteur Ltd.
SIGA Technologies, Inc.
Soligenix, Inc.
Xoma Corporation
(Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.)
1 Introduction 6
1.1 Industry Definition and Research Scope 6
1.1.1 Industry Definition 6
1.1.2 Research Scope 7
1.2 Research Methodology 10
1.2.1 Overview of Market Research Methodology 10
1.2.2 Market Assumption 11
1.2.3 Secondary Data 11
1.2.4 Primary Data 11
1.2.5 Data Filtration and Model Design 13
1.2.6 Market Size/Share Estimation 14
1.2.7 Research Limitations 15
1.3 Executive Summary 16
2 Market Overview and Dynamics 18
2.1 Market Size and Forecast 18
2.2 Major Growth Drivers 19
2.3 Market Restraints and Challenges 22
2.4 Emerging Opportunities and Market Trends 25
2.5 Porter’s Fiver Forces Analysis 29
3 Segmentation of Asia Pacific Market by Product 33
3.1 Market Overview by Product 33
3.2 Vaccines 35
3.2.1 Anthrax 38
3.2.2 Smallpox 39
3.2.3 Botulism 40
3.2.4 Nuclear/Radiation 41
3.2.5 E-Bola 42
3.2.6 Zika 43
3.2.7 Other Vaccines 44
3.3 Biothreat Detection Devices 45
3.4 Antibiotics 47
3.5 Masks 48
3.6 Other Products 49
4 Segmentation of Asia Pacific Market by Sales Channel 50
4.1 Market Overview by Sales Channel 50
4.2 Online Sales 52
4.3 Offline Sales 53
5 Segmentation of Asia Pacific Market by Application 54
5.1 Market Overview by Application 54
5.2 Military 56
5.3 Civilian 57
6 Asia-Pacific Market 2019-2030 by Country 58
6.1 Overview of Asia-Pacific Market 58
6.2 Japan 61
6.3 China 64
6.4 Australia 66
6.5 India 68
6.6 South Korea 70
6.7 Rest of APAC Region 72
7 Competitive Landscape 74
7.1 Overview of Key Vendors 74
7.2 New Product Launch, Partnership, Investment, and M&A 77
7.3 Company Profiles 78
Achaogen, Inc. 78
Alexeter Technologies LLC 80
Alnylam Pharmaceuticals, Inc. 81
Altimmune, Inc. 82
Bavarian Nordic AS 83
BioFactura, Inc. 84
Cleveland Biolabs, Inc. 85
Dynavax Technologies Inc 86
Dynport Vaccine Company LLC (DVC) 87
Elusys Therapeutics, Inc. 88
Emergent BioSolutions Inc 89
General Dynamics Corp. 90
GlaxoSmithKline Plc 91
Ichor Medical Systems 92
Mediimmune (AstraZeneca) 93
Nanotherapeutics, Inc. 94
Ology Bioscience 95
PathSensors Inc 96
Pluristem Therapeutics 97
Sanofi Pasteur Ltd. 98
SIGA Technologies, Inc. 99
Soligenix, Inc. 100
Xoma Corporation 101
8 Investing in Asia Pacific Market: Risk Assessment and Management 102
8.1 Risk Evaluation of Asia Pacific Market 102
8.2 Critical Success Factors (CSFs) 105
Related Reports and Products 108
Table 1. Snapshot of Asia Pacific Biodefense Market, 2019-2030 17
Table 2. Main Product Trends and Market Opportunities in Asia Pacific Biodefense Market 25
Table 3. Asia Pacific Biodefense Market by Product, 2019-2030, $ mn 33
Table 4. Asia Pacific Biodefense Market: Vaccines by Application, 2019-2030, $ mn 36
Table 5. List of Biodefense Vaccine Pipelines 37
Table 6. Asia Pacific Biodefense Market: Vaccines Biothreat Detection Devices by Type, 2019-2030, $ mn 46
Table 7. Asia Pacific Biodefense Market by Sales Channel, 2019-2030, $ mn 50
Table 8. Asia Pacific Market by Application, 2019-2030, $ mn 54
Table 9. APAC Biodefense Market by Country, 2019-2030, $ mn 59
Table 10. Japan Biodefense Market by Product, 2019-2030, $ mn 63
Table 11. Japan Biodefense Market by Sales Channel, 2019-2030, $ mn 63
Table 12. Japan Biodefense Market by Application, 2019-2030, $ mn 63
Table 13. China Biodefense Market by Product, 2019-2030, $ mn 65
Table 14. China Biodefense Market by Sales Channel, 2019-2030, $ mn 65
Table 15. China Biodefense Market by Application, 2019-2030, $ mn 65
Table 16. Australia Biodefense Market by Product, 2019-2030, $ mn 67
Table 17. Australia Biodefense Market by Sales Channel, 2019-2030, $ mn 67
Table 18. Australia Biodefense Market by Application, 2019-2030, $ mn 67
Table 19. India Biodefense Market by Product, 2019-2030, $ mn 69
Table 20. India Biodefense Market by Sales Channel, 2019-2030, $ mn 69
Table 21. India Biodefense Market by Application, 2019-2030, $ mn 69
Table 22. South Korea Biodefense Market by Product, 2019-2030, $ mn 71
Table 23. South Korea Biodefense Market by Sales Channel, 2019-2030, $ mn 71
Table 24. South Korea Biodefense Market by Application, 2019-2030, $ mn 71
Table 25. Biodefense Market in Rest of APAC by Country, 2019-2030, $ mn 73
Table 26. Achaogen, Inc.: Company Snapshot 78
Table 27. Achaogen, Inc.: Business Segmentation 78
Table 28. Achaogen, Inc.: Product Portfolio 79
Table 29. Achaogen, Inc.: Revenue, 2016-2018, $ mn 79
Table 30. Achaogen, Inc.: Recent Developments 79
Table 31. Risk Evaluation for Investing in Asia Pacific Market, 2019-2030 103
Table 32. Critical Success Factors and Key Takeaways 106
